Vulvovaginal candidiasis: evolution of a therapeutic approachs

Authors

  • М. В. Медведев Dnepropetrovsk Medical Academy, Ukraine

DOI:

https://doi.org/10.18370/2309-4117.2015.22.29-32

Keywords:

vulvovaginal candidiasis, fungi Candida, butoconazole, technology VagiSite, biofilm, Gynofort

Abstract

Vulvovaginal candidiasis – one of the most common causes of vaginitis symptoms among women of reproductive age: 75% of women faced with this disease at least once in their lives. Fungi Candida is well known cause of vulvovaginal candidiasis. 85–95% of all strains of yeasts isolated from patients with vaginal candidiasis belong to Candida albicans. It is proved butoconazole that has a high efficacy in eradicating fungi Candida and high speed relief of symptoms. A bioadhesive technology VagiSite (emulsion “water in oil”), used in the preparation of a 2% butoconazole nitrate Gynofort allows butoconazole permanently retained on wet vaginal mucous, slowly releasing

Author Biography

М. В. Медведев, Dnepropetrovsk Medical Academy

MD, professor, Obstetrics and Gynecology Department

References

  1. Sobel, J. D. “Vulvovaginal candidosis.” Lancet, 9577(2007) (Vol. 369): 1961–1971.
  2. E ckert, L.O., Hawes, S.E., Stevens, C.E., Koutsky, L.A., et al. “Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm.” Obstet Gynecol, 5(92) (1998): 757–765.
  3. O dds, F.C., Webster, C.E., Mayuranathan, P., Simmons, P.D. “Candida concentrations in the vagina and their association with signs and symptoms of vaginal candidosis.” J Med Vet Mycol, 5(26) (1988): 277–283.
  4. Landers, D.V., Wiesenfeld, H.C., Heine, R.P., Krohn, M.A., Hillier, S.L. “Predictive value of the clinical diagnosis of lower genital tract infection in women.” Am J Obstet Gynecol, 4(190) (2004): 1004–1010.
  5. N yirjesy, P., Alexander, A.B., Weitz, M.V. “Vaginal Candida parapsilosis: pathogen or bystander?” Infect Dis Obstet Gynecol, 1(13) (2005): 37–41.
  6. Soloviova, A.V., Plaksina, N.D., Silvestrova, G.A. “Vulvovaginal candidiasis: how to avoid recurrence.” Female doctor, 2(52) (2014): 49–55.
  7. Beigi, R.H., Meyn, L.A., Moore, D.M., Krohn, M.A., Hillier, S.L. “Vaginal yeast colonization in non-pregnant women: a longitudinal study.” Obstet Gynecol, 5(104) (2004): 926–930.
  8. Geiger, A.M., Foxman, B. “Risk factors for vulvovaginal candidiasis: a case-control study among university students.” Epidemiology, 2(7) (1996): 182–187.
  9. C haim, W., Foxman, B., Sobel, J.D. “Association of recurrent vaginal candidiasis and secretory ABO and Lewis phenotype.” J Infect Dis, 3(176) (1997): 828–830.
  10. C otch, M.F., Hillier, S.L., Gibbs, R.S., Eschenbach, D.A. “Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group.” Am J Obstet Gynecol, 2(178) (1998): 374–380.
  11. D ennerstein, G.J., Ellis, D.H. “Oestrogen, glycogen and vaginal candidiasis.” Aust N Z J Obstet Gynaecol, 3(41) (2001): 326–328.
  12. T arry, W., Fisher, M., Shen, S., Mawhinney, M. “Candida albicans: the estrogen target for vaginal colonization.” J Surg Res, 2(129) (2005): 278–282.
  13. Foxman, B. “The epidemiology of vulvovaginal candidiasis: risk factors.” Am J Public Health, 3(80) (1990): 329–331.
  14. M ahmoudi Rad, M., Zafarghandi, S., Abbasabadi, B., Tavallaee M. “The epidemiology of Candida species associated with vulvovaginal candidiasis in an Iranian patient population.” Eur J Obstet Gynecol Reprod Biol, 2(155) (2011): 199–203.
  15. Fidel, P.L. Jr., Vazquez, J. A., Sobel, J.D. “Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.” Clin Microbiol Rev, 1(12) (1999): 80–96.
  16. D e Leon, E.M., Jacober, S.J., Sobel, J.D., Foxman, B. “Prevalence and risk factors for vaginal Candida colonization in women with type 1 and type 2 diabetes.” BMC Infect Dis, 2(2002): 1.
  17. Goswami, R., Dadhwal, V., Tejaswi, S., Datta, K., Paul, A., et al. “Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status.” J Infect, 2(41) (2000): 162–166.
  18. D onders, G.G., Prenen, H., Verbeke, G., Reybrouck R. “Impaired tolerance for glucose in women with recurrent vaginal candidiasis.” Am J Obstet Gynecol, 4(187) (2002): 989–993.
  19. Spinillo, A., Capuzzo, E., Acciano, S., De Santolo, A., Zara, F. “Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis.” Am J Obstet Gynecol, 1(180) Pt. 1 (1999): 14–7.
  20. W ilton, L., Kollarova, M., Heeley, E., Shakir S. “Relative risk of vaginal candidiasis after use of antibiotics compared with antidepressants in women: postmarketing surveillance data in England.” Drug Saf, 8(26) (2003): 589–597.
  21. P irotta, M.V., Gunn, J.M., Chondros, P. “"Not thrush again!" Women's experience of post-antibiotic vulvovaginitis.” Med J Aust, 1(179) (2003): 43–46.
  22. Bluestein, D., Rutledge, C., Lumsden, L. “Predicting the occurrence of antibiotic-induced candidal vaginitis (AICV).” Fam Pract Res J, 3(11) (1991): 319–326.
  23. P ultz, N.J., Stiefel, U., Ghannoum, M., Helfand, M.S., Donskey, C.J. “Effect of parenteral antibiotic administration on establishment of intestinal colonization by Candida glabrata in adult mice.” Antimicrob Agents Chemother, 1(49) (2005): 438–440.
  24. Bradshaw, C.S., Morton, A.N., Garland, S.M., Morris, M. B., et al. “Higher-risk behavioral practices associated with bacterial vaginosis compared with vaginal candidiasis.” Obstet Gynecol, 1(106) (2005): 105–114.
  25. R eed, B.D., Zazove, P., Pierson, C.L., Gorenflo, D.W., Horrocks, J. “Candida transmission and sexual behaviors as risks for a repeat episode of Candida vulvovaginitis.” J Womens Health (Larchmt), 10(12) (2003): 979–989.
  26. Sobel, J. D. “Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis.” Am J Obstet Gynecol, 7(152) Pt. 2 (1985): 924–935.
  27. M iles, M.R., Olsen, L., Rogers, A. “Recurrent vaginal candidiasis. Importance of an intestinal reservoir.” JAMA , 17(238) (1977): 1836–1837.
  28. C hong, P.P., Lee, Y.L., Tan, B.C., Ng, K.P. “Genetic relatedness of Candida strains isolated from women with vaginal candidiasis in Malaysia.” J Med Microbiol, 8(52) (2003): 657–666.
  29. Garcia-Tamayo, J., Castillo, G., Martinez, A.J. “Human genital candidiasis: histochemistry, scanning and transmission electron microscopy.” Acta Cytol, 1(26) (1982): 7–14.
  30. King, R.D., Lee, J.C., Morris, A.L. “Adherence of Candida albicans and other Candida species to mucosal epithelial cells.” Infect Immun, 2(27) (1980): 667–674.
  31. Bertholf, M.E., Stafford, M.J. “Colonization of Candida albicans in vagina, rectum, and mouth.” J Fam Pract, 5(16) (1983): 919–924.
  32. A l-Hedaithy, S.S. “Spectrum and proteinase production of yeasts causing vaginitis in Saudi Arabian women.” Med Sci Monit, 7(8) (2002): 498–501.
  33. Zarnowski, R., Westler, W.M., Lacmbouh, G.A., Marita, J. M., Bothe J. R., et al. “Novel entries in a fungal biofilm matrix encyclopedia.” MBio, 4(5) (2014): e01333–14.
  34. Seidman, L.S., Skokos, C.K. “An evaluation of butoconazole nitrate 2% site release vaginal cream (Gynazole-1) compared to fluconazole 150 mg tablets (Diflucan) in the time to relief of symptoms in patients with vulvovaginal candidiasis.” Infect Dis Obstet Gynecol, 4(13) (2005): 197–206.
  35. Van Heusden, A.M., Merkus, H.M., Euser, R., Verhoeff, A. “A randomized, comparative study of a single oral dose of fluconazole versus a single topical dose of clotrimazole in the treatment of vaginal candidosis among general practitioners and gynaecologists.” Eur J Obstet Gynecol Reprod Biol, 2(55) (1994): 123–127.
  36. Brown, D., Henzl, M.R., Kaufman, R.H. “Butoconazole nitrate 2% for vulvovaginal candidiasis. New, single-dose vaginal cream formulation vs. seven-day treatment with miconazole nitrate. Gynazole 1 Study Group.” J Reprod Med, 11(44) (1999): 933–938.
  37. E xpert Board of Polish Gynecological Society “The statement of Polish Gynecological Society Experts on the treatment of acute vulvovaginal candidiasis with prolonged releasing 2% butoconazole nitrate vaginal cream--state of art in 2008.” Ginekol Pol, 4(80) (2009): 303–311.
  38. Thompson, D., Saul Levinson, R. “The bioadhesive system of local drug administration.” Women's Health, 3(27) (2006): 1–4.

Downloads

Published

2015-04-14

How to Cite

Медведев, М. В. (2015). Vulvovaginal candidiasis: evolution of a therapeutic approachs. REPRODUCTIVE ENDOCRINOLOGY, (22), 29–32. https://doi.org/10.18370/2309-4117.2015.22.29-32

Issue

No. 22 (2015)

Section

Inflammatory diseases

License

Copyright (c) 2015 М. В. Медведев

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

    1. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.